Mr
Matthew
Johnson

Partner & Patent Attorney

Manchester Office

Chemistry

Telephone. +44(0) 161 247 4900
Mobile. +44(0) 738 487 7684
Email. [email protected]

Experience

Matthew has extensive experience relating to the pharmaceutical industry, having started his career in medicinal chemistry at GSK where he delivered small molecule development candidates for neurological indications, such as Alzheimer's Disease and neuropathic and inflammatory pain.

Matthew specializes in obtaining and defending rights relating to pharmaceutical subject matter including new chemical entities, crystal forms, synthetic processes, intermediates, formulations, combination products and medical uses. In addition to European patent drafting and prosecution, Matthew also manages the prosecution of patent portfolios worldwide, and also has experience of obtaining Supplementary Protection Certificates (SPCs) in many European countries.

He regularly provides advice to clients on EPO opposition and appeal strategy and has successfully defended and attacked patent rights covering various commercial products via the central opposition procedure at the EPO. Matthew also regularly assist his clients with due diligence activities associated with in-licencing, such as freedom-to-operate opinions.

Besides pharmaceuticals, Matthew regularly assists his clients obtain and defend patent rights in relation to agrochemicals, catalysis, polymers, cleantech and food science.

Qualifications

Patent Attorney

Chartered (UK)
European


MCHEM

Chemistry and Pharmacology

POSTGRADUATE DIPLOMA OR CERTIFICATE

Certificate in Intellectual Property Law

OTHER

Patent Attorney Litigator

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.